B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
AVIR
AteaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings company update kept the core thesis intact: C-BEYOND remains on track for mid-2026 topline, C-FORWARD is still progressing toward year-end 2026 data, and cash of $256.0 million supports operations through 2027, which gives AVIR time to reach its main HCV inflection points without an immediate financing need [#8-K-2026-05-12] [#10-Q-2026-05-12].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.5.
What can break
C-BEYOND is the dominant near-term value driver, so a weak or delayed mid-2026 topline readout would likely overwhelm the cash-backed valuation.
Momentum
76
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.20Analysis 2026-05-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $8.50
Why
Momentum76 · Δ7d +7.6
Value41 · Δ7d 0.0
Sentiment58 · Δ7d +1.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +1.5.
Contradictions & invalidation
- • C-BEYOND is the dominant near-term value driver, so a weak or delayed mid-2026 topline readout would likely overwhelm the cash-backed valuation.
- • Management says current cash should fund planned operations through 2027, but the 10-Q also states capital needs could rise sooner than expected if assumptions prove wrong or if development timelines expand [#10-Q-2026-05-12].
- • The quarter did not add de-risking clinical data; it mainly reaffirmed timelines while R&D spend rose to $41.1 million and net loss widened to $45.4 million, so investors are still underwriting a low-coverage biotech with one dominant binary Phase 3 driver and only an early HEV backup [#8-K-2026-05-12].
Catalyst clock
2026-07-01
C-BEYOND Phase 3 topline remains the key mid-2026 inflection
Lead driver: Sentiment · See AI snapshot
Momentum
76
9% active weight
Current posture
7d trendImproving
Δ7d
+7.6
Δ21d
+9.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
58
62% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
-6.5
Why this grade
Composite grade C. Momentum 76.1 / Value 41.2 / Sentiment 58.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$418.67M
Beta
0.23
Shares Out
80.2M
P/E (TTM) · Derived
-2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.72
Rev YoY
-100.0%
EPS YoY
-7.3%
Gross Margin
+99.9%
Op Margin
-
Net Debt
-$300.99M
Current Ratio
8.13
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data